Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis
Authors:
- Melissa M. De MezaMMMelissa M. De Meza
- Willeke A. M. BlokxWBWilleke A. M. Blokx
- Johannes J. BonenkampJBJohannes J. Bonenkamp
- Christian U. BlankCBChristian U. Blank
- Maureen J. B. AartsMAMaureen J. B. Aarts
- Franchette W. P. J. van Den BerkmortelFBFranchette W. P. J. van Den Berkmortel
- Marye J. Boers-SonderenMBMarye J. Boers-Sonderen
- Jan Willem B. De GrootJan Willem B. De Groot
- John B. A. G. HaanenJHJohn B. A. G. Haanen
- Geke A. P. HospersGHGeke A. P. Hospers
- Ellen KapiteijnEllen Kapiteijn
- Olivier J. Van NotONOlivier J. Van Not
Open Access
Abstract
Adjuvant BRAF/MEK- and anti-PD-1 inhibition have significantly improved recurrence-free survival (RFS) compared to placebo in resected stage III BRAF-mutant melanoma. However, data beyond the clinical trial setting are limited. This study describes the toxicity and survival of patients treated with adjuvant BRAF/MEK inhibitors and compares outcomes to adjuvant anti-PD-1. For this study, stage III BRAF V600 mutant cutaneous melanoma patients treated with adjuvant BRAF/MEK-inhibition or anti-PD-1 were identified from the Dutch Melanoma Treatment Registry. BRAF/MEK- and anti-PD-1-treated patients were matched based on propensity scores, and RFS at 12 and 18 months were estimated. Between 1 July 2018 and 31 December 2021, 717 patients were identified. Of these, 114 patients with complete records were treated with BRAF/MEK therapy and 532 with anti-PD-1. Comorbidities (p = 0.04) and geographical region (p < 0.01) were associated with treatment choice. In 45.6% of BRAF/MEK-treated patients, treatment was prematurely discontinued. Grade ≥ 3 toxicity occurred in 11.5% of patients and was the most common cause of early discontinuation (71.1%). At 12 and 18 months, RFS in BRAF/MEK-treated patients was 85% and 70%, compared to 68% and 68% in matched anti-PD-1-treated patients (p = 0.03). In conclusion, comorbidities and geographical region determine the choice of adjuvant treatment in patients with resected stage III BRAF-mutant melanoma. With the currently limited follow-up, BRAF/MEK-treated patients have better RFS at 12 months than matched anti-PD-1-treated patients, but this difference is no longer observed at 18 months. Therefore, longer follow-up data are necessary to estimate long-term effectiveness.Keywords
This publication has 30 references indexed in Scilit:
- Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the NetherlandsEuropean Journal of Cancer, 2017
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsThe Lancet Oncology, 2016
- Data Analysis2016
- A comparison of 12 algorithms for matching on the propensity scoreStatistics in Medicine, 2013
- The use of propensity score methods with survival or time‐to‐event outcomes: reporting measures of effect similar to those used in randomized experimentsStatistics in Medicine, 2013
- Dates and Times Made Easy withlubridateJournal of Statistical Software, 2011
- The Split-Apply-Combine Strategy for Data Analysis2011
- Methods to assess intended effects of drug treatment in observational studies are reviewedJournal of Clinical Epidemiology, 2004
- Prognostic Factors in Metastatic Melanoma: A Pooled Analysis of Eastern Cooperative Oncology Group TrialsJournal of Clinical Oncology, 2000
- The Robust Inference for the Cox Proportional Hazards ModelJournal of the American Statistical Association, 1989